Kazia Therapeutics Ltd (KZIA)

$0.28225

Market is closed - opens 7 PM, 23 May 2024

Insights on Kazia Therapeutics Ltd

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 555.0 → 5.0 (in $), with an average decrease of 99.1% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 3 quarters, -3.43M → -8.82M (in $), with an average decrease of 64.1% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 58.5% return, outperforming this stock by 136.0%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 232.5% return, outperforming this stock by 329.4%

Performance

  • $0.27
    $0.29
    $0.28
    downward going graph

    3.57%

    Downside

    Day's Volatility :6.86%

    Upside

    3.41%

    downward going graph
  • $0.19
    $1.34
    $0.28
    downward going graph

    33.36%

    Downside

    52 Weeks Volatility :86.07%

    Upside

    79.1%

    downward going graph

Returns

PeriodKazia Therapeutics LtdIndex (Russel 2000)
3 Months
-5.91%
0.0%
6 Months
-59.74%
0.0%
1 Year
-77.46%
0.0%
3 Years
-96.91%
-20.1%

Highlights

Market Capitalization
7.2M
Book Value
$0.2
Earnings Per Share (EPS)
-0.37
Wall Street Target Price
2.06
Profit Margin
0.0%
Operating Margin TTM
-9.999999999E7%
Return On Assets TTM
-46.42%
Return On Equity TTM
-186.37%
Revenue TTM
560.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
35.6%
Gross Profit TTM
555.0
EBITDA
-17.5M
Diluted Eps TTM
-0.37
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
0.0
EPS Estimate Next Year
0.0
EPS Estimate Current Quarter
0.0
EPS Estimate Next Quarter
0.0

Analyst Recommendation

Buy
    80%Buy
    20%Hold
    0
    0%Sell
Based on 5 Wall street analysts offering stock ratings for Kazia Therapeutics Ltd(by analysts ranked 0 to 5 stars)
Based on 5 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
4
4
4
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 629.85%

Current $0.28
Target $2.06

Technicals Summary

Sell

Neutral

Buy

Kazia Therapeutics Ltd is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Kazia Therapeutics Ltd
Kazia Therapeutics Ltd
-25.25%
-59.74%
-77.46%
-96.91%
-90.91%
Moderna, Inc.
Moderna, Inc.
37.56%
83.82%
13.37%
-12.47%
553.14%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
10.42%
24.29%
32.26%
98.6%
210.52%
Novo Nordisk A/s
Novo Nordisk A/s
7.9%
30.89%
58.53%
230.87%
458.51%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
10.52%
25.13%
30.01%
109.26%
156.43%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Kazia Therapeutics Ltd
Kazia Therapeutics Ltd
NA
NA
NA
0.0
-1.86
-0.46
NA
0.2
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-6.46
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
29.16
29.16
1.46
44.2
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
45.83
45.83
2.36
3.5
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
28.9
28.9
0.53
17.11
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Kazia Therapeutics Ltd
Kazia Therapeutics Ltd
Buy
$7.2M
-90.91%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$54.0B
553.14%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$108.8B
210.52%
29.16
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$592.1B
458.51%
45.83
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$115.1B
156.43%
28.9
39.46%

Institutional Holdings

  • Armistice Capital, LLC

    9.39%

  • Junked Platinum Investment Management Ltd

    6.91%

  • Morgan Stanley - Brokerage Accounts

    0.76%

  • Bank of Montreal

    0.53%

  • BMO Capital Markets Corp.

    0.53%

  • HSBC Holdings PLC

    0.24%

Company Information

innovative. focused. agile. kazia therapeutics is an agile, oncology-focused biotechnology company, based in sydney, australia. we have two clinical staged drug development candidates and an early stage discovery program, across a range of oncology indications. our lead program is gdc-0084, a small molecule inhibitor of the pi3k / akt / mtor pathway, which is being developed to treat glioblastoma multiforme, the primary and most aggressive form of brain cancer. licensed from genentech in late 2016, gdc-0084 is anticipated to enter phase ii clinical trials in 2017. trxe-002-1, or cantrixil is kazia’s second drug development candidate under development as a treatment for ovarian cancer. the chemotherapeutic is currently undergoing a phase 1 clinical trial in hospitals across australia and the united states. initial data on this trial is expected to be reported early in 2018. kazia therapeutics is trading under the following tickers: asx: kza nasdaq: kzia for more information, please visi

Organization
Kazia Therapeutics Ltd
Employees
0
CEO
Dr. John Edwin Friend II, M.D.
Industry
Health Technology

Discover More

FAQs